Business
BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer
Company’s bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to...
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"image","alt":"BullFrog AI Holdings, Inc.","displaySize":"","headline":null,"caption":"BullFrog AI Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/40a6d1d7288dd7624185c5755b024c0e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cckXAhHY1jCBABonzk6CjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/40a6d1d7288dd7624185c5755b024c0e","width":300,"height":73}},"lazy":false},{"type":"text","content":"Company’s bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI","length":179,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, highlights the presentation of data derived from the use of the Company’s proprietary platform bfLEAP® with pancreatic cancer trial data to identify an almost three times increase in mean survival from the control to treatment arms. The data will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on Jan. 9 at poster session B.","length":678,"tagName":"p"},{"type":"text","content":"The presentation, in collaboration with Eleison Pharmaceuticals and the Moffitt Cancer Center, is titled, “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” and will subsequently appear in the Journal of Clinical Oncology (JCO) supplement corresponding to the symposium.","length":311,"tagName":"p"},{"type":"text","content":"“The glufosfamide case study in pancreatic cancer successfully showcased the utility of our platform to provide drug developers with an end-to-end analytical tool engineered to resolve multimodal biological complexity at scale,” said BullFrog AI Founder and CEO Vin Singh. “Too much time and capital are wasted in drug development traveling down incorrect pathways, ultimately leaving patients without effective treatments. The power of bfLEAP® and bfPREP™ is their ability to give drug devel...